US 12,458,610 B2
Pharmaceutical composition for treating or preventing diabetic cataract
Hong Seog Seo, Seoul (KR); Yong Jik Lee, Incheon (KR); Jong-Suk Song, Seoul (KR); and Youngsub Eom, Seoul (KR)
Assigned to Korea University Research and Business Foundation, Seoul (KR)
Appl. No. 17/421,826
Filed by KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, Seoul (KR)
PCT Filed Jan. 10, 2020, PCT No. PCT/KR2020/000479
§ 371(c)(1), (2) Date Jul. 9, 2021,
PCT Pub. No. WO2020/145728, PCT Pub. Date Jul. 16, 2020.
Claims priority of application No. 10-2019-0003369 (KR), filed on Jan. 10, 2019.
Prior Publication US 2022/0096403 A1, Mar. 31, 2022
Int. Cl. A61K 31/165 (2006.01); A61P 27/12 (2006.01)
CPC A61K 31/165 (2013.01) [A61P 27/12 (2018.01)] 12 Claims
OG exemplary drawing
 
1. A method for treating diabetic cataract, comprising:
administering a pharmaceutical composition comprising midodrine or a pharmaceutically acceptable salt thereof as an active ingredient to a subject;
measuring expression levels of aldose reductase and TNFα in a cell of the subject before the administering and after the administering; and
confirming that the expression levels after the administering are decreased from the expression levels before the administering.